BACKGROUND: Recent studies have identified a high frequency of Clostridium difficile infections in patients with active inflammatory bowel disease. AIMS: To retrospectively assess the determinants and results of Clostridium difficile testing upon the admission of patients hospitalized with active inflammatory bowel disease in a tertiary care centre and to determine the predicting factors of Clostridium difficile infections. METHODS: We reviewed all admissions from January 2008 and December 2010 for inflammatory bowel disease flare-ups. A toxigenic culture and a stool cytotoxicity assay were performed for all patients tested for Clostridium difficile. RESULTS: Out of 813 consecutive stays, Clostridium difficile diagnostic assays have been performed in 59% of inpatients. The independent predictive factors for the testing were IBD (ulcerative colitis: OR 2.0, 95% CI 1.5-2.9; p<0.0001) and colonic involvement at admission (OR 2.2, 95% CI 1.5-3.1, p<0.0001). Clostridium difficile infection was present in 7.0% of the inpatients who underwent testing. In a multivariate analysis, the only independent predictor was the intake of nonsteroidal anti-inflammatory drugs within the two months before admission (OR 3.8, 95% CI 1.2-12.3; p=0.02). CONCLUSIONS: Clostridium difficile infection is frequently associated with active inflammatory bowel disease. Our study suggests that a recent intake of nonsteroidal anti-inflammatory drugs is a risk factor for inflammatory bowel disease -associated Clostridium difficile infection.
BACKGROUND: Recent studies have identified a high frequency of Clostridium difficileinfections in patients with active inflammatory bowel disease. AIMS: To retrospectively assess the determinants and results of Clostridium difficile testing upon the admission of patients hospitalized with active inflammatory bowel disease in a tertiary care centre and to determine the predicting factors of Clostridium difficileinfections. METHODS: We reviewed all admissions from January 2008 and December 2010 for inflammatory bowel disease flare-ups. A toxigenic culture and a stool cytotoxicity assay were performed for all patients tested for Clostridium difficile. RESULTS: Out of 813 consecutive stays, Clostridium difficile diagnostic assays have been performed in 59% of inpatients. The independent predictive factors for the testing were IBD (ulcerative colitis: OR 2.0, 95% CI 1.5-2.9; p<0.0001) and colonic involvement at admission (OR 2.2, 95% CI 1.5-3.1, p<0.0001). Clostridium difficileinfection was present in 7.0% of the inpatients who underwent testing. In a multivariate analysis, the only independent predictor was the intake of nonsteroidal anti-inflammatory drugs within the two months before admission (OR 3.8, 95% CI 1.2-12.3; p=0.02). CONCLUSIONS:Clostridium difficileinfection is frequently associated with active inflammatory bowel disease. Our study suggests that a recent intake of nonsteroidal anti-inflammatory drugs is a risk factor for inflammatory bowel disease -associated Clostridium difficileinfection.
Authors: Juan Muñoz-Miralles; Bruno C Trindade; Pablo Castro-Córdova; Ingrid L Bergin; Leslie A Kirk; Fernando Gil; David M Aronoff; Daniel Paredes-Sabja Journal: Future Microbiol Date: 2018-09-21 Impact factor: 3.165
Authors: Walker Julliard; Travis J De Wolfe; John H Fechner; Nasia Safdar; Rashmi Agni; Joshua D Mezrich Journal: Ann Surg Date: 2017-06 Impact factor: 12.969
Authors: William Sangster; John P Hegarty; Kathleen M Schieffer; Justin R Wright; Jada Hackman; David R Toole; Regina Lamendella; David B Stewart Journal: Front Microbiol Date: 2016-05-25 Impact factor: 5.640
Authors: Dae Bum Kim; Kang-Moon Lee; Sang Hyoung Park; You Sun Kim; Eun Soo Kim; Jun Lee; Sung-Ae Jung; Geom Seog Seo; Ji Min Lee Journal: Intest Res Date: 2018-04-30